Gleevec

Pharma

Aerovate's stock plummets after sole product fails in PAH trial

The company is scrapping future development of its lead and only program, an inhaled version of Novartis' Gleevec, in pulmonary arterial hypertension.

Zoey Becker Jun 17, 2024 7:25pm

ASCO: Novartis' Scemblix proves benefits over Gleevec in CML

May 31, 2024 8:00am

Takeda's Iclusig tops Novartis' Gleevec decisively in Ph+ALL

Feb 14, 2023 5:00pm

In Ph+ALL trial, Takeda's Iclusig outdoes Novartis' Gleevec

Nov 17, 2022 10:27am

ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix

May 26, 2022 5:00pm

Deciphera cracks the door open for off-label cancer drug use

Jan 25, 2022 12:02pm